Cardio3 BioSciences will be present at Oddo Midcap Forum

Cardio3 BioSciences will be present at Oddo Midcap Forum

Cardio3 BioSciences to address American institutional investors in January at J.P. Morgan Healthcare Conference

Cardio3 BioSciences to address American institutional investors in January at J.P. Morgan Healthcare Conference

Cardio3 BioSciences announces Q3 2014 business update

Cardio3 BioSciences announces Q3 2014 business update

Cardio3 BioSciences acquires CorQuest Medical Inc.

Cardio3 BioSciences acquires CorQuest Medical Inc.

Cardio3 BioSciences appoints Dr. Warren Sherman as Chief Medical Officer

Cardio3 BioSciences appoints Dr. Warren Sherman as Chief Medical Officer

Joint clarification regarding agreement between Cardio3 BioSciences and Mayo Clinic

Joint clarification regarding agreement between Cardio3 BioSciences and Mayo Clinic

Cardio3 BioSciences awarded preferred access rights to all Mayo Clinic Center for Regenerative Medecine Portolio

Cardio3 BioSciences awarded preferred access rights to all Mayo Clinic Center for Regenerative Medecine Portolio

Cardio3 BioSciences announces new business development strategy to broaden its product pipeline

Cardio3 BioSciences announces new business development strategy to broaden its product pipeline

Cardio3 BioSciences reports 2014 half year financial results ans business update

Cardio3 BioSciences reports 2014 half year financial results ans business update

Cardio3 BioSciences Announces Secondary Placement With New Institutional Investors

Cardio3 BioSciences Announces Secondary Placement With New Institutional Investors

Cardio3 BioSciences Announces Completion of its Capital Increase of €25 Million at €44 per share.

Cardio3 BioSciences Announces Completion of its Capital Increase of €25 Million at €44 per share.

Cardio3 BioSciences teams up with Medisun International to create Cardio3 BioSciences Asia Holdings Ltd, a Joint Venture aimed at conducting pivotal clinical programs in Greater China

Cardio3 BioSciences teams up with Medisun International to create Cardio3 BioSciences Asia Holdings Ltd, a Joint Venture aimed at conducting pivotal clinical programs in Greater China